Abbott Laboratories (NYSE:ABT) has significantly outperformed the broader S&P 500 index this year, with its stock price rising 18% compared to the S&P 500’s 6% gain. This strong performance stems from ...

9 analysts have shared their evaluations of Abbott Laboratories (NYSE:ABT) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table provides a quick ...

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Abbott Laboratories’ stock narrative is shifting as analysts adjust their consensus price target, which has edged down slightly from $144.47 to $144.43. This recent update comes alongside a range of ...

An announcement from Abbott Laboratories ( ($ABT) ) is now available. On December 12, 2025, Abbott Laboratories announced the ...

Abbott Laboratories (NYSE:ABT – Get Free Report) had its price objective upped by equities research analysts at Morgan Stanley from $117.00 to $127.00 in a note issued to investors on ...

Abbott Laboratories (NYSE:ABT – Get Free Report) had its price target increased by analysts at Jefferies Financial Group from $135.00 to $137.00 in a research note issued on Thursday,Benzinga reports.

A more conservative goal of $100 monthly dividend income would require 508 shares of Abbott. An investor would need to own $325,274 worth of Abbott Laboratories to generate a monthly dividend income ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Disclosed on November 25, Eric Shroff, Senior Vice President at Abbott Laboratories (NYSE:ABT), executed a substantial insider sell as per the latest SEC filing. What Happened: Shroff's decision to ...